Lake Street lowered the firm’s price target on Tela Bio (TELA) to $3 from $6 and keeps a Buy rating on the shares following Q3 results that “were short of the Street” and 2025 and 2026 guidance that was down on prolonged sales force disruption. The firm believes shares could be range bound in the near-term, but also thinks the recapped balance sheet and reset outlook will “provide the team an opportunity to exceed expectations,” the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELA:
- Strategic Initiatives and Financial Adjustments Underpin Buy Rating for TELA Bio Despite Short-term Challenges
- Tela Bio price target lowered to $4 from $7 at Canaccord
- TELA Bio’s Earnings Call: Growth Amid Challenges
- TELA Bio Secures $70M Loan for Growth Initiatives
- Tela Bio price target lowered to $1.25 from $2 at Piper Sandler